Slide 1
Image is not available

Our mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases.

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis

• Imcyse and Pfizer to collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis

• Pfizer to lead clinical development and commercialization activities

• Imcyse to receive upfront payment in cash and through the purchase of equity in addition to milestone up to $180 million and tiered royalty payments

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today announced Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes.Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today announced Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes.

  • Subsidy for €1.1 million over a period of 29 months to support the development of a therapeutic vaccination treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Funds will be used to demonstrate PoC, establish the clinical relevance of the NMOSD ImotopeTM approach and lead to a Phase I clinical trial 

  • NMOSD is a rare and severe autoimmune disease of the central nervous system dominated by inflammation of the optic nerve and spinal cord with an estimated incidence between 1-2 per 100,000

Page 2 of 4

Address

Headquarters:

Avenue Pré-Aily 14
4031 Liège (Angleur)
BELGIUM

Phone : +32 (0)4 325 1100

Contact